Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

AstraZeneca : Serum Institute gets approval to resume India trial of AstraZeneca COVID vaccine

share with twitter share with LinkedIn share with facebook
09/16/2020 | 06:36am EDT
FILE PHOTO: A test tube labelled with the Vaccine is seen in front of Covid-19 and stock graph logo in this illustration taken

Serum Institute of India has received Indian regulatory approval to resume local clinical trials of AstraZeneca's potential COVID-19 vaccine, a source familiar with the matter said on Wednesday.

The approval came from the Drugs Controller General of India (DCGI), according to the source.

AstraZeneca has resumed British clinical trials of the vaccine, one of the most advanced in development for COVID-19, after they were paused earlier this month following a serious side effect in a trial participant.

Trials have also resumed in Brazil and South Africa, but remain on hold in the United States.

Indian regulators had allowed Serum's trials of the AstraZeneca vaccine to resume under certain conditions, including increased safety monitoring and informing volunteers about new findings, a DCGI source said.

"We allowed them (to resume trials) after a detailed discussion with authorities in the UK and the company itself," the source added.

Serum, the world's biggest vaccine manufacturer, did not respond to Reuters requests for comment, while DCGI representatives did not respond to emails seeking comment.

(Reporting by Euan Rocha in Mumbai, Neha Dasgupta in New Delhi and Sachin Ravikumar in Bengaluru; Editing by Anil D'Silva and Shounak Dasgupta)

share with twitter share with LinkedIn share with facebook
All news about ASTRAZENECA PLC
09/25JOHNSON & JOHNSON, NIKE, ILLUMINA : Stocks That Defined the Week
09/25Canada's biggest provinces seek clampdown on social gatherings as coronavirus..
09/25Europe takes new action against Apple, Boeing’s 737 MAX flying soon?
09/25What you need to know about the coronavirus right now
09/25EXCLUSIVE : AstraZeneca gets partial immunity in low-cost EU vaccine deal
09/25AstraZeneca gets partial immunity in low-cost EU vaccine deal
09/25Eu paid lower price for astrazeneca vaccine in return for partial liability -..
09/25Astrazeneca granted partial shield against side-effect claims in eu covid vac..
09/25NOVAVAX : initiates late-stage COVID-19 vaccine trial in UK
09/24Pfizer partner BioNTech sees no role for its vaccine in UK challenge trial
More news
Financials (USD)
Sales 2020 26 694 M - -
Net income 2020 3 079 M - -
Net Debt 2020 13 082 M - -
P/E ratio 2020 50,6x
Yield 2020 2,58%
Capitalization 143 B 143 B -
EV / Sales 2020 5,86x
EV / Sales 2021 5,14x
Nbr of Employees 70 600
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 117,86 $
Last Close Price 109,30 $
Spread / Highest target 42,2%
Spread / Average Target 7,83%
Spread / Lowest Target -39,6%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC12.74%142 957
JOHNSON & JOHNSON-0.14%383 497
ROCHE HOLDING AG5.40%304 339
MERCK & CO., INC.-8.82%209 750
PFIZER, INC.-8.73%200 326
NOVARTIS AG-12.61%190 402